GENEVANT SCIENCES, INC.

MA

Business/legal/admin.for tech-focused nucleic acid development and delivery company

Filings
10
Firms Hired
1
Total Expenses
Years Active
2023–2025

Filings

YearFirmPeriodExpensesDoc
2025 NOVEL STRATEGIES (FKA) PRISM GROUP 2nd Quarter (Apr 1 - June 30)
2nd Quarter - Termination
2025 NOVEL STRATEGIES (FKA) PRISM GROUP 1st Quarter (Jan 1 - Mar 31)
1st Quarter - Report
2024 NOVEL STRATEGIES (FKA) PRISM GROUP 4th Quarter (Oct 1 - Dec 31)
4th Quarter - Report
2024 NOVEL STRATEGIES (FKA) PRISM GROUP 3rd Quarter (July 1 - Sep 30)
3rd Quarter - Report
2024 NOVEL STRATEGIES (FKA) PRISM GROUP 2nd Quarter (Apr 1 - June 30)
2nd Quarter - Report
2024 NOVEL STRATEGIES (FKA) PRISM GROUP 1st Quarter (Jan 1 - Mar 31)
1st Quarter - Report
2023 NOVEL STRATEGIES (FKA) PRISM GROUP 4th Quarter (Oct 1 - Dec 31)
4th Quarter - Report
2023 NOVEL STRATEGIES (FKA) PRISM GROUP 2nd Quarter (Apr 1 - June 30)
AMENDED
2023 NOVEL STRATEGIES (FKA) PRISM GROUP 3rd Quarter (July 1 - Sep 30)
3rd Quarter - Report
2023 NOVEL STRATEGIES (FKA) PRISM GROUP 2nd Quarter (Apr 1 - June 30)
Registration
Firms Hired
FirmFilingsExpenses
NOVEL STRATEGIES (FKA) PRISM GROUP 10
Issue Areas
IssueActivities
Health Issues 10